

PRESS RELEASE
01 February 2023 08:30:00 CET

Groves Medical Group starts offering Stockholm3 in the UK

Groves Medical Group has started offering Stockholm3 for prostate cancer testing. This is the first UK clinic that uses Stockholm3.

Stockholm3 will be offered to men aged 45 to 74 in the South-West London area. The blood samples will be taken at the Groves Medical Centre in New Malden, London and the test analysis will be performed by A3P at its lab facility in Uppsala, Sweden. Men found to have an elevated risk for prostate cancer may be offered an MRI examination at New Malden Diagnostic Centre and referred to a urologist for further treatment if required. Groves Medical Group works closely with Sterling Health Group that offers a wide range of secondary care treatment options.

“Prostate cancer is the most common cancer in men in the UK, and about one in eight men will be diagnosed with prostate cancer in their lifetime. Early detection is of utmost importance for therapy success, but the commonly used PSA test has its shortcomings in terms of precision as it sounds off a false alarm too often, and still misses a lot of aggressive cases in need of treatment. Stockholm3 is a new more accurate test based on solid data from studies involving some 75,000 men. It has been shown to reduce overtreatment such as unnecessary biopsies by around 50 percent, and even more importantly, it finds twice as many cases of aggressive cancer compared to PSA. We are therefore very happy that we can now offer Stockholm3 to our patients to improve treatment and in the long run save lives,” says Dr. Jeremy Harris, GP & Partner of Groves Medical Group.

“We see a growing interest for Stockholm3 all over Europe. The test is now available to British men for the first time and I believe that it can play an important role in the UK for improving early detection and at the same time save costs through reducing overtreatment,” says David Rosén, CEO of A3P Biomedical.

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

(1) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

[Groves Medical Group starts offering Stockholm3 in the UK](#)